NCT05933044 - RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada | Biotech Hunter

Enrollment

662

Participants

Timeline

Start Date

November 19, 2021

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Durvalumab

Chemoradiotherapy plus durvalumab

Trial Locations (5)

University of Calgary, Calgary

BC Cancer, Vancouver

Queen Elizabeth (QE) II Health Sciences Centre, Halifax

The Ottawa Hospital, Ottawa

Centre hospitalier de l'Université de Montréal (CHUM), Montreal